Efficacy, Tolerance, and Pharmacokinetics of Once Daily Tobramycin for Pseudomonas Exacerbations in Cystic Fibrosis

Archives of Disease in Childhood- United Kingdom

doi 10.1136/adc.78.6.536

Full Text

Abstract

Available in

Categories

Date

June 1, 1998

Authors

C Arrouet-Lagande

Publisher

BMJ

Related search

The Pharmacokinetics and Toxicity of Morning vs. Evening Tobramycin Dosing for Pulmonary Exacerbations of Cystic Fibrosis: A Randomised Comparison

Journal of Cystic Fibrosis

Respiratory Medicine

English

Glucose Tolerance During Pulmonary Exacerbations in Children With Cystic Fibrosis

Multidisciplinary

English

Initial Pseudomonas Aeruginosa Treatment Failure Is Associated With Exacerbations in Cystic Fibrosis

Pediatric Pulmonology

Respiratory Medicine

English

Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis

Cardiovascular Medicine

Intensive Care Medicine

Respiratory Medicine

English

Safety, Efficacy and Convenience of Tobramycin Inhalation Powder in Cystic Fibrosis Patients: The EAGER Trial

Journal of Cystic Fibrosis

Respiratory Medicine

English

In Vitro Activity of Amiloride Combined With Tobramycin Against Pseudomonas Isolates From Patients With Cystic Fibrosis.

Antimicrobial Agents and Chemotherapy

Infectious Diseases

English

Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations

English

Breakpoints for Predicting Pseudomonas Aeruginosa Susceptibility to Inhaled Tobramycin in Cystic Fibrosis Patients: Use of High-Range Etest Strips

Journal of Clinical Microbiology

English

Bayesian Estimation of Tobramycin Exposure in Patients With Cystic Fibrosis

Antimicrobial Agents and Chemotherapy

Infectious Diseases

English